New combo therapy trial launches for Hard-to-Treat cancers
NCT ID NCT07176975
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 30 times
Summary
This early-phase study tests a new drug, BI 1831169, combined with an existing cancer immunotherapy (anti-PD1 antibody) in Japanese adults with advanced solid tumors that have spread or no longer respond to standard treatments. The main goal is to find the highest safe dose of the combination and monitor any side effects. Up to 46 participants will receive the treatment as an infusion for up to one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.